Moreover, the ablation of FAP+α‐SMA+ CAFs in pancreatic cancer has paradoxically accelerated tumor progression, highlighting the complexity and potential risks of indiscriminate CAF targeting. This evidence concerns the gene ACTA1 and neoplasm.